Literature DB >> 25627046

Evaluation of percutaneous ethanol injections in benign thyroid nodules.

Camila Luhm Silva Perez1, Tayane Muniz Fighera1, Fabiola Miasaki1, Cleo Otaviano Mesa Junior1, Gilberto Jorge da Paz Filho1, Hans Graf1, Gisah Amaral de Carvalho1.   

Abstract

OBJECTIVE: The objective of this study was to evaluate the efficacy and safety of percutaneous ethanol injection (PEI) in the treatment of benign thyroid nodules. SUBJECTS AND METHODS: We evaluated 120 patients with benign thyroid nodules. Patients underwent evaluation of serum TSH and free T4, cervical ultrasound, and thyroid scintigraphy (in those with suppressed TSH levels). The application of sterile ethanol 99% was guided by ultrasound, with the injected volume amounting to one-third of the nodule volume. Response was considered complete (reduction of 90%); partial (reduction between 50 and 90%); or none (reduction of < 50%). Autonomous nodules were evaluated for normalization of TSH levels.
RESULTS: Among the nodules studied, 30.8% were solid, 56.7% were mixed, 12.5% were cystic, and 21.6% were hyperfunctioning. The initial volume of the treated nodules ranged from 0.9 to 74.8 mL (mean 13.1 ± 12.4 mL). We performed 1-8 sessions of PEI, applying an average of 6.2 mL of ethanol for patient. After 2 years of follow-up, 17% of patients achieved a complete response (94% reduction); 53%, a partial response (70% reduction); and 30%, no response. A reduction in the volume of autonomous nodules was noted in 70% of cases, and 54% had a normalized value of TSH. The main side effect is local pain, lasting less than 24 hours in most cases.
CONCLUSION: This study showed that PEI is a safe and effective procedure for treatment of benign, solid or mixed thyroid nodules. Most cases resulted in significant reduction in nodule volume, with normalization of thyroid function.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25627046     DOI: 10.1590/0004-2730000003444

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  5 in total

1.  mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation: a prospective study.

Authors:  S Mazzeo; R Cervelli; R Elisei; G Tarantini; C Cappelli; E Molinaro; D Galleri; L De Napoli; C Comite; R Cioni; P Vitti; D Caramella
Journal:  J Endocrinol Invest       Date:  2018-04-23       Impact factor: 4.256

2.  Histopathological Evidence of the Efficacy of Percutaneous Ethanol Injection in the Treatment of Axillary Osmidrosis: A Promising New Procedure.

Authors:  Ali Asilian; Bahareh Abtahi-Naeini; Masoom Shahbazi
Journal:  Skin Appendage Disord       Date:  2017-08-31

3.  Efficacy and Safety of Ultrasound-Guided Percutaneous Polidocanol Sclerotherapy in Benign Cystic Thyroid Nodules: Preliminary Results.

Authors:  Xiaohua Gong; Qi Zhou; Fang Wang; Wenjun Wu; Xiaojun Chen
Journal:  Int J Endocrinol       Date:  2017-05-31       Impact factor: 3.257

4.  Ultrasound-Guided Percutaneous Ethanol Injection Protocol to Treat Solid and Mixed Thyroid Nodules.

Authors:  João Soares Felício; Antônio Maria Silva Conceição; Flávia Marques Santos; Michelle Masuyo Minami Sato; Fabíola de Arruda Bastos; Ana Carolina Contente Braga de Souza; Camila Cavalcante Koury; João Felício Abrahão Neto; Franciane Trindade Cunha de Melo; Carolina Tavares Carvalho; Thaís Pontes Arbage; Antonio Bentes de Figueiredo Junior; Hana Andrade de Rider Brito; Marcelo Oliveira Mourão Júnior; Fabricio de Souza Resende; Amanda Soares Peixoto; Karem Miléo Felício
Journal:  Front Endocrinol (Lausanne)       Date:  2016-06-06       Impact factor: 5.555

5.  Efficacy of Ethanol Ablation for Benign Thyroid Cysts and Predominantly Cystic Nodules: A Systematic Review and Meta-Analysis.

Authors:  Cheng-Chun Yang; Yung Hsu; Jyun-Yan Liou
Journal:  Endocrinol Metab (Seoul)       Date:  2021-02-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.